Synopsis
Recognise threatened or infected upper-tract drainage, coordinate resuscitation and urgent decompression, and track recovery, definitive stone treatment and removal of temporary devices.
- An obstructed kidney with infection or anuria is a urological emergency. Start assessment, resuscitation and indicated antibiotics while obtaining urgent urological source control; neither cultures nor response to an antibiotic should postpone drainage.
- NICE AKI guidance requires immediate urological referral for pyonephrosis, an obstructed solitary kidney, bilateral upper-tract obstruction or obstruction causing AKI complications. When stenting or nephrostomy treats obstruction with AKI, do it as soon as possible and within 12 hours of diagnosis.
- A ureteric stent and percutaneous nephrostomy are both effective decompression options. Choose the promptly achievable safe route from anatomy, physiology, bleeding risk and expertise, and defer definitive infected-stone removal until infection has resolved.
Reasoning priorities
Confirm the site and consequence of obstruction while resuscitation proceeds.
Use the fastest appropriate study for the actual question and patient. In suspected pyonephrosis with AKI, apply the NG148 immediate ultrasound within-six-hour requirement. CT can define a stone and alternative pathology when needed, but diagnostic sequencing must not create an avoidable delay in source control.
Worked reasoning
A sixty one year old man presents with rigors, right flank pain, systolic pressure 88 mmHg and creatinine 198 micromol/L from a baseline 92.
- He is recognised as having high-risk suspected sepsis. Ultrasound demonstrates right hydronephrosis, and urgent CT available during stabilisation identifies an eight-millimetre proximal ureteric stone. Blood and urine cultures are obtained promptly. Senior urology and anaesthesia agree urgent decompression while monitored resuscitation continues; the team does not wait for culture growth or a twelve-hour limit.
- An indicated 250 mL isotonic crystalloid bolus is given over 10–15 minutes with assessment of perfusion and breathing, and a second bolus is given after reassessment. For this individual, the microbiologist selects ceftriaxone 2 g IV every twenty four hours, infused over at least thirty minutes, using his recent susceptible urinary isolate and local resistance assessment after checking beta-lactam allergy and liver function. The first dose is administered within one hour; this selection is not a universal empirical regimen for every obstructed septic patient.
- A retrograde stent is placed promptly because access is feasible and this is the immediately available safe drainage route. Urine from above the obstruction is sent for culture; the stone is left for later treatment. Blood pressure rises to 112/70 mmHg, lactate falls on repeat testing and urine output recovers during monitored care. These observed changes support effective source control, while ongoing observations check for recurrent deterioration.
- Susceptibility confirms the selected ceftriaxone. At forty eight hours, route and response are reviewed and 2 g IV daily is continued while the total course is assessed against the systemic illness, the selected agent and effective drainage. At the eventual treatment-stop review, rigors and flank pain have resolved, perfusion and urine output remain normal, inflammatory markers have fallen and creatinine is 94 micromol/L. The record confirms that ceftriaxone continued for a further seventy two hours after documented defervescence. The completed course reflects the whole disease course and source-control assessment; it was not calculated simply by adding seventy two hours to the first normal temperature. This satisfies the afebrile branch of the product continuation instruction without claiming a universally sufficient total. EAU distinguishes the inferior seven-day result in male systemic UTI from limited beta-lactam evidence, so these observed stopping conditions are not presented as a fixed course for every man with an infected obstructed stone.
- After infection has resolved, planned ureteroscopy clears the stone. A dated device plan is fulfilled, with stent removal recorded and later assessment showing no residual obstruction and renal function at baseline. The completed record therefore demonstrates sepsis recovery, stone clearance and device removal as three separate outcomes.
Key medicines
Ceftriaxone, selected 2 g UK injection productFor an adult complicated urinary infection when selected using susceptibility and local policy: 1–2 g IV once daily; the worked high-risk case uses 2 g every 24 hours by infusion over at least 30 minutes. Review IV treatment at 48 hours. The selected SmPC states that duration varies with the disease course and ceftriaxone continues for 48–72 hours after the patient becomes afebrile or evidence of bacterial eradication is achieved. Assess that continuation criterion within the total-course decision, alongside source control, response and the population; it does not itself define a short total course. EAU reports seven days inferior to fourteen in male systemic UTI, while evidence for other agents is limited and older beta-lactam studies showed no clear benefit beyond ten days. Neither finding establishes a universal fixed ceftriaxone course for this male shock/obstruction context. The worked case records a completed course, sustained recovery and seventy two hours of treatment after defervescence, as an individual endpoint rather than a fixed course for other patients.Check allergy before administration: ceftriaxone or other cephalosporin hypersensitivity and previous severe hypersensitivity to another beta-lactam are contraindications. Do not mix with calcium-containing diluents or give simultaneously with IV calcium solutions; adult sequential use requires compatible line management and thorough flushing. Never inject a lidocaine-containing IM preparation intravenously. Renal impairment alone usually needs no reduction if hepatic function is satisfactory; CrCl below 10 mL/min limits the dose to 2 g/day. Severe combined renal and hepatic dysfunction requires close specialist monitoring. Check INR with vitamin K antagonists and monitor renal function, blood count and hepatic tests as the course requires. Stop and treat severe allergy or severe skin reactions; assess significant diarrhoea, new anaemia, confusion or myoclonus for drug toxicity. Renal or biliary precipitation is a recognised risk, so reassess new relevant symptoms. This is an adult example; pregnancy and neonates require their own restrictions.